{"id":"NCT04058366","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","officialTitle":"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-05","primaryCompletion":"2022-12-16","completion":"2022-12-16","firstPosted":"2019-08-15","resultsPosted":"2024-01-16","lastUpdate":"2024-01-16"},"enrollment":251,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This study evaluated the long-term safety, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes).","primaryOutcome":{"measure":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"From Baseline up to Week 100","effectByArm":[{"arm":"Part A: ELX/TEZ/IVA","deltaMin":241,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":84,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Ireland","Italy","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["37983082","33331662"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":251},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Headache","Cough","COVID-19","Diarrhoea"]}}